Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 41 of 1519 for:    child psychiatry

ADHD Medication and Predictors of Treatment Outcome (ADAPT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02136147
Recruitment Status : Enrolling by invitation
First Posted : May 12, 2014
Last Update Posted : July 9, 2019
Sponsor:
Information provided by (Responsible Party):
Linda Halldner Henriksson, Karolinska Institutet

Brief Summary:
ADHD medication of children and adolescents is becoming increasingly common. Clinical experience and scientific studies have proven that approximately 30% of children/adolescents with ADHD do not benefit from this treatment. However, there is insufficient knowledge about who these children are. All children and adolescents, who start treatment with ADHD medication at public Child and Adolescent Psychiatry units in Stockholm, on Gotland, an in Västerbotten, will be asked to participate in the study. The investigators intend to monitor the patients´clinical symptoms and possible side-effects after treatment start. The investigators will collect background information and saliva samples from the patient and his/her parents to be able to study if there are any genetic (hereditary) or other markers that can predict positive or negative outcomes of the ADHD medication. With this information, the investigators aim at, to a greater extent, be able to individualize treatment choices for children and adolescents with ADHD without unnecessary, costly and possibly unfavorable treatment attempts.

Condition or disease Intervention/treatment
Attention Deficit Disorder With Hyperactivity (ADHD) Drug: methylphenidate medication Drug: atomoxetine medication Drug: lisdexamphetamine medication Drug: guanfacine medication

Detailed Description:

The specific aims for the ADAPT study are:

  1. Investigate if certain gene polymorphisms are associated with poor effect of ADHD drugs (non-responders).
  2. Investigate if other biologically, phenotypic or psychosocial factors are associated with poor effect of ADHD drugs (non-responders).
  3. Investigate if the frequency of side-effects of ADHD drugs differs between children with different genotypes.
  4. Investigate if the frequency of side-effects of ADHD drugs differs between children with different phenotypic and/or psychosocial factors

Method:

This study has a naturalistic design. The aim is to map all new treatments with ADHD drugs at all 13 public BUP units in Stockholm County, one BUP unit on Gotland, and three BUP units in Västerbotten Region. The participation means that medication is initiated as planned in normal clinical practice by the child´s ordinary physician, and beyond this only means a somewhat denser and more structured follow-up. In addition, the investigators will ask for saliva samples from the patient and his/her parents. The investigators aim at including at least 1000 individuals in total in the study.

Part of the data will be collected via the national Quality Register for ADHD Treatment Follow-up (BUSA), which has approved security procedures approved by the Swedish Data Inspection Board.

Case report forms are computerized and separate from the database registry for collected study data. The database and detailed variable lists are constructed in collaboration with professional database managers.

Standard Operation Procedures are designed in collaboration by project coordinator, study nurse and principal investigator, and may be revised after pilot phase.

Collected samples will be stored at KI biobank.

Data analysis:

  1. To judge if the patient is a responder to ADHD drugs the SNAP-IV rating of ADHD symptoms (before and after medication start) is used. The patients who at 3 months have an at least 40% reduction in SNAP-IV score are reckoned "responders" and those who at the same time point have a less than 20% change in SNAP-IV score are reckoned "non-responders". Differences between the groups will be analyzed with logistic regression, with responder status as depending variable, and genotype and the other risk markers (biological, phenotypic, and psychosocial markers) as independent variables after correction for symptoms at baseline. Even a 50% drop-out rate will (i.e. 1000 out of estimated 2000 eligible individuals) give a 98% power to identify a 49% increase in non-responder proportion for a specific genotype.
  2. Concomitantly, the outcome in side-effects, heart rate, blood pressure, weight (z-score) and length (z-score) will be analyzed with linear regression with the same independent variables.
  3. The analyses are performed separately for each ADHD drug.
  4. There are significantly more boys than girls (about 4:1) with ADHD. Given the sex difference in prevalence it is obvious to also include sex as a covariate in our analyses of treatment outcome.
  5. Missing data will be treated according to the principles of complete case and multiple imputation.

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 2000 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 12 Months
Official Title: Naturalistic Study of ADHD Medication and Predictors of Treatment Outcome
Study Start Date : June 2015
Estimated Primary Completion Date : December 2020

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Children with ADHD medication
Identified responders and non-responders in children/adolescents starting medication for treatment of ADHD in public child and adolescent psychiatric services in Stockholm, on Gotland, and in Västerbotten.
Drug: methylphenidate medication
Other Names:
  • N06BA04
  • Concerta
  • Ritalin
  • Equasym
  • Medikinet

Drug: atomoxetine medication
Other Names:
  • N06BA09
  • Strattera

Drug: lisdexamphetamine medication
Other Names:
  • N06BA12
  • Elvanse

Drug: guanfacine medication
Other Names:
  • C02AC02
  • Intuniv

Lisdexamphetamine medication
Identified responders and non-responders in children/adolescents starting medication with lisdexamphetamine in public child and adolescent psychiatric services in Stockholm and on Gotland.
Drug: lisdexamphetamine medication
Other Names:
  • N06BA12
  • Elvanse

Atomoxetine medication
Identified responders and non-responders in children/adolescents starting medication with atomoxetine in public child and adolescent psychiatric services in Stockholm and on Gotland.
Drug: atomoxetine medication
Other Names:
  • N06BA09
  • Strattera

Methylphenidate medication
Identified responders and non-responders in children/adolescents starting medication with methylphenidate in public child and adolescent psychiatric services in Stockholm and on Gotland.
Drug: methylphenidate medication
Other Names:
  • N06BA04
  • Concerta
  • Ritalin
  • Equasym
  • Medikinet

Guanfacine medication
Identified responders and non-responders in children/adolescents starting medication with guanfacine in public child and adolescent psychiatric services in Stockholm and on Gotland.
Drug: guanfacine medication
Other Names:
  • C02AC02
  • Intuniv




Primary Outcome Measures :
  1. change in SNAP-IV Teacher and Parent rating scale (Swanson, Nolan and Pelham ADHD Rating Scale) [ Time Frame: at 3 months follow-up ]
    ADHD symptoms

  2. change in P-SEC (Pediatric Side Effects Checklist) [ Time Frame: at 3 months follow-up ]
    Side-effect measure


Secondary Outcome Measures :
  1. change in C-GAS (Children´s global assessment scale) [ Time Frame: at 12 months follow-up ]
    global functioning measure

  2. change in CGI-S (Clinical Global Impression- of Severity) [ Time Frame: at 12 months follow-up ]
    disease severity

  3. change in SNAP-IV Teacher and Parent rating scale [ Time Frame: at 1 month follow-up ]
    ADHD symptoms

  4. change in SNAP-IV Teacher and Parent rating scale [ Time Frame: at 6 months follow-up ]
    ADHD symptoms

  5. change in SNAP-IV Teacher and Parent rating scale [ Time Frame: at 12 months follow-up ]
    ADHD symptoms

  6. change in P-SEC (Pediatric Side Effects Checklist) [ Time Frame: at 1 month follow-up ]
    side effect measure

  7. change in P-SEC (Pediatric Side Effects Checklist) [ Time Frame: at 6 months follow-up ]
    side effect measure

  8. change in P-SEC (Pediatric Side Effects Checklist) [ Time Frame: at 12 months follow-up ]
    side effect measure

  9. change in Spence Children's Anxiety Scale (SCAS) [ Time Frame: at 1 month follow-up ]
    symptoms of anxiety

  10. change in Spence Children's Anxiety Scale (SCAS) [ Time Frame: at 3 months follow-up ]
    symptoms of anxiety

  11. change in Spence Children's Anxiety Scale (SCAS) [ Time Frame: at 6 months follow-up ]
    symptoms of anxiety

  12. change in Spence Children's Anxiety Scale (SCAS) [ Time Frame: at 12 months follow-up ]
    symptoms of anxiety

  13. change in heart rate [ Time Frame: at 1 month follow-up ]
  14. change in heart rate [ Time Frame: at 3 months follow-up ]
  15. change in heart rate [ Time Frame: at 6 months follow-up ]
  16. change in heart rate [ Time Frame: at 12 months follow-up ]
  17. change in systolic blood pressure [ Time Frame: at 1 month follow-up ]
  18. change in systolic blood pressure [ Time Frame: at 3 months follow-up ]
  19. change in systolic blood pressure [ Time Frame: at 6 months follow-up ]
  20. change in systolic blood pressure [ Time Frame: at 12 months follow-up ]
  21. change in diastolic blood pressure [ Time Frame: at 1 month follow-up ]
  22. change in diastolic blood pressure [ Time Frame: at 3 months follow-up ]
  23. change in diastolic blood pressure [ Time Frame: at 6 months follow-up ]
  24. change in diastolic blood pressure [ Time Frame: at 12 months follow-up ]
  25. change in weight z-score [ Time Frame: at 1 month follow-up ]
  26. change in weight z-score [ Time Frame: at 3 months follow-up ]
  27. change in weight z-score [ Time Frame: at 6 months follow-up ]
  28. change in weight z-score [ Time Frame: at 12 months follow-up ]
  29. change in height z-score [ Time Frame: at 6 months follow-up ]
  30. change in height z-score [ Time Frame: at 12 months follow-up ]
  31. change in Autism Spectrum Screening Questionnaire (ASSQ) score [ Time Frame: at 3 months follow-up ]
    symptoms of autism

  32. change in Autism Spectrum Screening Questionnaire (ASSQ) score [ Time Frame: at 1 months follow-up ]
    symptoms of autism

  33. change in Autism Spectrum Screening Questionnaire (ASSQ) score [ Time Frame: at 6 months follow-up ]
    symptoms of autism

  34. change in Autism Spectrum Screening Questionnaire (ASSQ) score [ Time Frame: at 12 months follow-up ]
    symptoms of autism


Other Outcome Measures:
  1. change in self-harm frequency [ Time Frame: at 12 months follow-up ]
    change in self-harm frequency behavior as noted in the quality register BUSA

  2. change in suicide attempt frequency [ Time Frame: at 12 months follow-up ]
    change in suicide attempt frequency as reported in quality register BUSA


Biospecimen Retention:   Samples With DNA
Saliva


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All children/adolescents starting ADHD medication at the public child and adolescent psychiatry services in Stockholm and on Gotland
Criteria

Inclusion Criteria:

  • Clinical diagnosis of ADHD
  • Starting medication against ADHD symptoms with atomoxetine, methylphenidate, lisdexamphetamine, or guanfacine

Exclusion Criteria: Any medication against ADHD the last 3 months


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02136147


Locations
Layout table for location information
Sweden
Division for Child and Adolescent Psychiatry in Stockholm
Stockholm, Stockholm County, Sweden
Sponsors and Collaborators
Karolinska Institutet

Additional Information:

Layout table for additonal information
Responsible Party: Linda Halldner Henriksson, MD, PhD, Karolinska Institutet
ClinicalTrials.gov Identifier: NCT02136147     History of Changes
Other Study ID Numbers: ADAPT
LS 1110-1339 ( Other Grant/Funding Number: ALF/PPG )
SLS-309701 ( Other Grant/Funding Number: Stiftelsen Söderström-Königska sjukhemmet )
First Posted: May 12, 2014    Key Record Dates
Last Update Posted: July 9, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by Linda Halldner Henriksson, Karolinska Institutet:
Attention Deficit Disorder with Hyperactivity
Neuropsychiatry
Drug therapy
Pharmacogenetics
Child Psychiatry
Additional relevant MeSH terms:
Layout table for MeSH terms
Hyperkinesis
Attention Deficit Disorder with Hyperactivity
Attention Deficit and Disruptive Behavior Disorders
Neurodevelopmental Disorders
Mental Disorders
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Guanfacine
Methylphenidate
Lisdexamfetamine Dimesylate
Atomoxetine Hydrochloride
Central Nervous System Stimulants
Physiological Effects of Drugs
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Adrenergic Uptake Inhibitors
Adrenergic Agents
Antihypertensive Agents
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists